189 related articles for article (PubMed ID: 24649045)
1. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.
Zhou Y; Peng L; Li Y; Chen L
Biomed Rep; 2013 Nov; 1(6):873-878. PubMed ID: 24649045
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Lian S; Zhang X; Zhang Y; Zhao Q
Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
5. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Jo SJ; Shin H; Jo S; Kwon O; Myung SK
Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Kao YS; Lo CH; Tu YK; Hung CH
Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
Chen M; Zhang L; Wang Q; Shen J
PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
[TBL] [Abstract][Full Text] [Related]
14. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
15. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
16. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Corrie PG; Bulusu R; Wilson CB; Armstrong G; Bond S; Hardy R; Lao-Sirieix S; Parashar D; Ahmad A; Daniel F; Hill M; Wilson G; Blesing C; Moody AM; McAdam K; Osborne M
Br J Cancer; 2012 Aug; 107(4):585-7. PubMed ID: 22814578
[TBL] [Abstract][Full Text] [Related]
17. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis - systematic review and Bayesian network meta-analysis.
Ramasubbu MK; Maji S; Padhan M; Maiti R; Hota D; Majumdar SKD; Srinivasan A
BMJ Support Palliat Care; 2022 Dec; ():. PubMed ID: 36564149
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
